Comparative Pharmacokinetics of YH14659

• Status: Completed
• Trial end date: 2011-12-01
• Target enrollment: 0
• Participant gender: Male

Summary

The objective of this study is to compare pharmacokinetics after single oral administration of 2 capsules of YH14659, a fixed-dose combination of clopidogrel and aspirin developed by Yuhan Corporation versus co-administration of Plavix (clopidogrel) and Astrix (aspirin) in healthy male volunteers.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Yuhan Corporation
• Treatments: Aspirin; Clopidogrel

Criteria

Inclusion Criteria:

• The patient or legally authorized representative must sign a written informed consent, prior to the any procedure, using a form that is approved by the local Institutional Review Board after detail explanation of the purpose, contents, and characteristic of the drug

• Healthy male volunteers of aged between 20 years to 55 years

• Have standard weight of ≤ ±20% based on Broca index* (Broca index: ideal weight(kg) = (height(cm)-100) x 0.9)

• Have no history of neither congenital nor chronic disease

• Have no history of abnormal symptoms or opinions as a result of physical examination (medical checkup)

• Eligible subjects with acceptable medical history, physical examination laboratory tests, ECG during screening period

Exclusion Criteria:

• Received any drug that induce or/and inhibit drug metabolizing enzyme such as barbital within the last 28 days prior to the first administration

• Shown symptoms doubtful as an acute disease within the last 28 days prior to the first administration

• Have signs of bleeding symptoms or/and history of disease such as: gum bleeding, hard to control hemorrhage, easily suffer from bruise, and etc.

• Have disease that can affect absorption, distribution, metabolism and excretion of the drug such as: inflammatory bowel disease, gastric ulcer, duodenal ulcer, hepatic disorders, and gastrointestinal tract surgery except appendectomy

• Have a known allergy(except mild allergic rhinitis which does not require treatment) or hypersensitivity to drugs

• Have the following abnormal findings on diagnosis;

• have AST or ALT > 1.25 times of normal upper limit

• have total bilirubin > 1.5 times of normal upper limit

• have higher PT, aPPT, BT than normal range

• have PLT below 150,000 or above 350,000

• Have been drug abuse, excessive caffeine (> 5 cups/day), heavy smoking (>10 cigarettes/day), continuous alcohol intake (> 30g/day) or have drunk within the last 7 days prior to the first administration

• Have been on a diet that can affect absorption, distribution, metabolism and excretion of the drug (especially grapefruit juice 7 days prior to the first administration)

• Donated blood within 60 days prior to the first administration

• Participated in any other clinical trials within 60 days prior to the first administration

• Have used any drug which is thought to affect this study by principal investigator 10 days prior to the first administration

• Subject who is judged to be ineligible by principal investigator or sub-investigator